Stay updated with breaking news from Current Prescribing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Teva and MedinCell Announce FDA Approval of UZEDY™ Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of... | April 29, 2023
This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1 In a Phase 3 clinical trial, UZEDY demonstrated
XARACOLL 300mg Dose Cohort Experienced Less Pain and XARACOLL was Generally Well Tolerated with an Adverse Event Profile Comparable to the Current Prescribing Information Innocoll Pharmaceuticals